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Autosomal recessive forms of Parkinson’s disease are caused by mutations in three genes:
 
Parkin, PINK1, and DJ-1.These genes encode for proteins with distinct enzymatic activities
 
that may work together to confer neuroprotection. Parkin is an E3 ubiquitin ligase that has  
been shown to ubiquitinate substrates and to trigger proteasome-dependent degradation  
or autophagy, two crucial homeostatic processes in neurons. PINK1 is a mitochondrial pro-  
tein kinase whose activity is required for Parkin-dependent mitophagy, a process that has  
been linked to neurodegeneration. Finally, DJ-1 is a protein homologous to a broad class of  
bacterial enzymes that may function as a sensor and modulator of reactive oxygen species,  
which have been implicated in neurodegenerative diseases. Here, we review the literature  
on the structure and biochemical functions of these three proteins.  
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INTRODUCTION
Parkinson’s disease (PD) is a degenerative movement disorder
characterized by motor symptoms such as slowness of movement,
tremor, rigidity, and postural instability. The motor symptoms
are caused by the loss of dopaminergic neurons in the substan-
tia nigra (Schapira and Jenner, 2011; Venderova and Park, 2012).
Non-motor symptoms such as loss of olfaction, constipation, and
rapid eye movement (REM) sleep disorder are also central to PD
and can precede the motor symptoms. Although most cases of
PD are idiopathic, there are rare familial forms of the disease
that follow Mendelian inheritance patterns that can be traced to
single gene mutations (Martin et al., 2011). In particular, auto-
somal recessive PD is caused primarily by mutations in one of
three genes that encode proteins with distinct enzymatic activ-
ities: Parkin, PINK1, and DJ-1. Pathogenic mutations in these
genes include exonic rearrangements and missense or frameshift
mutations (Mata et al., 2004; Tan and Skipper, 2007). Since these
mutations lead to a loss of function, i.e., a reduced or abolished
activity in the corresponding protein (Martin et al., 2011), we
can infer that their normal function(s) prevent cell death. Thus a
better understanding of their biochemical activities will help deci-
pher the molecular mechanisms underlying neuronal cell death
that causes PD. Here we review recently published studies that
significantly advanced our understanding of the structure and bio-
chemical mechanisms employed by Parkin, PINK1, and DJ-1, and
highlight the knowledge gaps that need to be filled.
PARKIN
Parkin (PARK2) was the first gene associated with autosomal reces-
sive PD (Kitada et al., 1998; Lücking et al., 2000). Parkin is a
52 kDa protein with an N-terminal ubiquitin-like (Ubl) domain
followed by a 60 amino acid (a.a.) linker and four zinc-finger
domains (Figure 1). Early studies showed that Parkin is an E2-
dependent E3 ubiquitin ligase that binds UbcH7 and UbcH8
(Shimura et al., 2000; Zhang et al., 2000). An E3 ligase is an
enzyme that catalyzes the transfer of ubiquitin, a small 76 a.a.
protein, from an E2 ubiquitin-conjugating enzyme to a protein
substrate. Ubiquitinated substrates then undergo different fates
depending on the site and type of ubiquitination (described in
more details below). However, even today, its cellular function and
associated substrates remain controversial. Over the last decade,
Parkin has been implicated in numerous seemingly unrelated cel-
lular processes for which many substrates have been suggested
(reviewed in Dawson and Dawson, 2010). However, in recent years
much attention has converged on Parkin’s role in bioenergetics and
mitochondrial quality control pathways (reviewed in Exner et al.,
2012). Importantly, Parkin is recruited to depolarized mitochon-
dria where it drives their elimination by autophagy (mitophagy)
(Narendra et al., 2008). Interestingly, early studies in Drosophila
lacking Parkin revealed its crucial role in mitochondrial homeosta-
sis, and that proteomics studies in Parkin knockout mice showed
variations primarily in proteins involved in energy metabolism,
mitochondrial function and oxidative stress (Palacino et al., 2004;
Periquet et al., 2005). Parkin null mice were recently shown to be
acutely resistant to weight gain when fed on a high fat diet due to
reduced lipid uptake (Kim et al., 2011). Parkin was also shown to
be a p53-target gene that mediates the well-known role of p53 in
regulating glucose metabolism (Zhang et al., 2011), and regulates
the levels of PGC-1α, an important regulator of mitochondrial
biogenesis (Shin et al., 2011). Finally, Parkin was suggested to play
a role in the clearance of proteins damaged as a result of dopamine
oxidation, as well as in the metabolism of dopamine (Jiang et al.,
2004, 2012). These processes all require the ligase activity of Parkin,
but the precise molecular mechanisms that underlie these cellular
processes remain obscure.
Elucidating the mechanism of ubiquitination by Parkin is
crucial for understanding its biological function. The last three
zinc-finger domains form an RING1, In-Between, RING2 (RBR)
module, which is found in many other E3 ubiquitin ligases such
as HHARI, HOIP, HOIL, and Dorfin (Wenzel and Klevit, 2012). A
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FIGURE 1 | Biochemical mechanism and structure of Parkin. (A)
Two-step mechanism for substrate ubiquitination by Parkin. The first step
(transthiolation) is the transfer of ubiquitin from a thioester bond on a
cysteine on an E2 enzyme to a thioester bond on Parkin Cys431. The
second step (acyl transfer) is the formation of an isopeptide bond on a
substrate amino group, typically a lysine side-chain. (B) Structure of Parkin.
The domain boundaries of full-length human Parkin and selected PD
mutations are displayed at the top. The structures of individual domains
from Parkin or RBR homologs are shown below. Zinc atoms are displayed
as gray spheres.
major breakthrough in our understanding of Parkin function was
the discovery that RBR proteins use a two-step catalytic mech-
anism similar to that used by HECT ubiquitin ligases (Wenzel
et al., 2011). The discovery stemmed from the observation that
the E2 enzyme UbcH7 can only discharge ubiquitin onto cys-
teine, as opposed to other E2s like UbcH5C that can discharge
on cysteine or lysine. Consequently, E3 ligases that are able to use
UbcH7 as a conjugating enzyme, like HECT ligases, must bear
an acceptor cysteine. In RBR ligases, this cysteine is located in the
RING2 domain. Thus in the first reaction (transthiolation), the C-
terminus of ubiquitin is transferred from an E2 enzyme’s cysteine
to the acceptor cysteine, resulting in the formation of a thioester
intermediate (Figure 1). In Parkin, the acceptor cysteine Cys431 is
required for its ubiquitin ligase activity (Zhang et al., 2000; Wenzel
et al., 2011) and the mutation C431F causes PD (Maruyama et al.,
2000), in agreement with its proposed role in catalysis. The second
step of the reaction (acyl transfer) involves the transfer of ubiqui-
tin C-terminus from the acceptor cysteine to an amino group on a
substrate, forming an isopeptide bond. This HECT-type catalytic
model has recently been confirmed for the E3 ligase HOIP, which
synthesizes linear polyubiquitin chains (Smit et al., 2012; Stieglitz
et al., 2012). Moreover, activation of Parkin upon mitochondrial
depolarization induces the HECT-like activity of Parkin, result-
ing in the formation of an oxyester Parkin∼Ub adduct for the
C431S mutant of Parkin (Lazarou et al., 2013). This model has
important functional implications for Parkin and may help resolve
apparent contradictions in the plethora of biochemical studies on
Parkin. For example, binding of E2 enzyme has been reported to
require an intact RBR module in cells: deletion of either RING1
or RING2 in Parkin abolished binding (Shimura et al., 2000).
Recently, the RING1 domain of HOIP was shown to be required
for its strong UbcH7-dependent activity, but not its weaker E2-
independent activity, as opposed to RING2 which was required
for both functions (Smit et al., 2012). Moreover, the sequence
similarity of the RBRs RING1 domain to other E2-binding RING
domains, which adopt the cross-brace zinc-binding topology, sug-
gest that it could be the initial docking site of an E2∼Ub complex.
Whether this implies that the E2 enzyme binds both RING1 and
RING2 simultaneously remains to be investigated.
The structure of an entire RBR module would shine light on
our understanding of how E2 enzymes bind Parkin and transfer
ubiquitin. Although the structure of full-length Parkin has yet to
be determined, structures of individual zinc-finger domains of
Parkin and RBR homologs are available (Figure 1). Parkin binds a
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total of eight zinc atoms and presumably each zinc-finger domain
binds two zinc atoms (Hristova et al., 2009). Indeed the structures
of the RBR protein RNF144A RING1 (pdb code 1wim, unpub-
lished) and the Parkin IBR (Beasley et al., 2007) have two bound
zinc atoms. However, the structure of HHARI RING2 binds only
one zinc atom (Capili et al., 2004). To resolve this apparent contra-
diction, a recent study suggested a novel mode of zinc coordination
by Parkin RING2, which comprises two zinc atoms: one bound by
Cys418, Cys421, Cys436, Cys441, and the other by Cys446, Cys449,
Cys457, and His461 (Rankin et al., 2011). The strong conservation
of these eight residues across Parkin orthologs and cysteine muta-
genesis studies (Wong et al., 2007) are consistent with this model,
which remains to be confirmed by structure determination. The
structure of Parkin RING2 could reveal how Cys431 can form a
thioester bond with ubiquitin and enable transfer to a substrate
amino group.
If the functions of RING1 and RING2 can be inferred from
structural and biochemical studies, the functions of the RING0
and IBR domains remain mysterious. The structure of the Parkin
IBR reveals a zinc-finger domain with an unusual zinc coordina-
tion topology (Beasley et al., 2007). The proximity of its N- and
C-termini led Beasley et al. to suggest a role in positioning RING1
and RING2 in proximity, which would be required for the transfer
of ubiquitin from a RING1-bound E2∼Ub complex to the accep-
tor cysteine in RING2. Mutagenesis studies in the zinc-binding
cysteines of HOIP IBR domain have indeed shown that the IBR
domain is required for its E2-dependent ubiquitin ligase activity
(Smit et al., 2012). In this respect, the structure of an entire RBR
module would give tremendous insights into the role of the IBR
domain. In Parkin, the RBR module is preceded by the RING0
domain, a non-classical zinc-finger that was suggested to adopt a
unusual hairpin topology based on weak sequence homology with
the cysteine-rich domain of bacterial DnaJ (Rankin et al., 2011).
The RING0 domain is unique to Parkin among RBR proteins and
is conserved in all its orthologs, suggesting it plays a conserved
function specific to Parkin. Future biochemical studies on Parkin
should specifically address the role of the IBR and RING0 domain
in its ubiquitin ligase activity.
One aspect of Parkin’s function that requires thorough inves-
tigation is the type of polyubiquitin chains that it forms. E3
ubiquitin ligases transfer ubiquitin carboxy-terminus from an
E2 cysteine thiol onto a protein primary amino group, typically
a lysine side-chain ε-amino group or an amino-terminus. The
acceptor protein can either be a substrate, or another ubiquitin
molecule. The latter give rises to polyubiquitin chains, which can
be linked through any of ubiquitin’s seven lysines (K6, K11, K27,
K29, K33, K48, or K63-linked chains) or its amino-terminus (lin-
ear chains). Using methylated or lysine-free (K0) ubiquitin, two
studies on Parkin’s in vitro ubiquitin ligase activity claimed that
Parkin mediates multiple monoubiquitination, both on itself and
on substrates (Hampe et al., 2006; Matsuda et al., 2006). This
activity was shown to require only the RING2 domain, as patho-
genic mutation in RING1 and IBR, as well as deletions containing
only IBR and RING2, did not significantly affect its ubiquitin lig-
ase activity. This contradicted earlier studies that showed both
RING1 and RING2 were required for E2-dependent ubiquitina-
tion with immunoprecipitated Parkin (Shimura et al., 2000), and
that Parkin can make K48 and K63 polyubiquitin chains in cells
using one lysine-only ubiquitin variants (Doss-Pepe et al., 2005;
Lim et al., 2005). More recently, Durcan et al. (2011) showed that
Parkin can form K6, K27, K29, and K63 chains in cells, and that
it can form polyubiquitin chains that are deconjugated by ataxin-
3 in vitro (Durcan et al., 2012). Upon recruitment of Parkin to
mitochondria depolarized with the proton ionophore carbonyl
cyanide m-chlorophenylhydrazone (CCCP), K27, and K63 lysine-
only ubiquitin variants were shown to accumulate on mitochon-
dria (Geisler et al., 2010). However, in a separate study, K48 and
K63-linked chains were directly detected by mass spectrometry
on CCCP-depolarized mitochondria in a Parkin-dependent man-
ner (Chan et al., 2011), and the same chains were also detected
on Mfn1 using linkage-specific antibodies (Lazarou et al., 2013).
Overall these studies strongly suggest that Parkin has the capacity
to synthesize polyubiquitin chains. In the light of the HECT-type
model recently proposed for RBR ligases (Wenzel et al., 2011),
Parkin could have intrinsic chain type specificity independently
of which E2 is used, as was shown for HECT E3 ligases (Kim
and Huibregtse, 2009) and the RBR-containing LUBAC complex
(Kirisako et al., 2006; Stieglitz et al., 2012). Recently, the IBR-
RING2 domains of Parkin were indeed shown in vitro to make
K48 chains in an E2-independent manner, although the assays
were carried out at a high pH (8.8), which can considerably affect
the reactivity of the nucleophiles involved in the ubiquitin transfer
reactions (Chew et al., 2011). The type of chains and the factors
involved in imparting linkage specificity to Parkin thus remain to
be determined.
A number of substrates of Parkin have been proposed, but how
most of them are recruited to Parkin is unknown. The prime sus-
pect for that function is the Ubl domain, a protein-protein inter-
action domain that has been shown to bind ubiquitin-interacting
motifs (UIM) (Sakata et al., 2003; Fallon et al., 2006), SH3 domains
(Trempe et al., 2009) as well as its own C-terminus (Chaugule
et al., 2011). A comparison of affinity constants shows that bind-
ing to the SH3 domain of endophilin-A and C-terminal of Parkin
is in the 1–10µM range (Trempe et al., 2009; Chaugule et al.,
2011), whereas binding to UIMs is >100µM (Safadi and Shaw,
2010). Structurally, the Ubl interacts with all its ligands via the
same surface centered on Ile44. A number of PD mutations are
found in the Ubl domain, implying that it is essential to the func-
tion of Parkin, although some mutations such as R42P unfold the
domain, which can lead to its aggregation and degradation (Henn
et al., 2005; Safadi et al., 2011). The Ubl domain is required for
some proposed functions of Parkin, such as endophilin-A ubiqui-
tination (Trempe et al., 2009) and the regulation of lipid uptake
through ubiquitin-mediated stabilization of the CD36 lipid trans-
porter (Kim et al., 2011). Although it is not known whether the Ubl
binds a mitochondrial ligand, it has been shown to be required for
efficient mitochondrial recruitment and mitophagy in two reports
(Narendra et al., 2010; Shiba-Fukushima et al., 2012), but not in
others (Geisler et al., 2010; Matsuda et al., 2010). This contra-
diction can be resolved by considering that Parkin without the
Ubl domain has slower recruitment kinetics, as shown recently by
Shiba-Fukushima et al. (2012). But since Parkin can be recruited to
the mitochondria without the Ubl, it seems unlikely that recruit-
ment to mitochondrial substrates such as mitofusin and Miro is
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mediated by the Ubl domain. However, PD mutants in the RING0
domain (K161N, K211N, C212Y) have strongly impaired mito-
chondrial recruitment and clearance activity (Geisler et al., 2010;
Matsuda et al., 2010; Narendra et al., 2010), raising the possibility
that the RING0 domain could mediate substrate recruitment on
mitochondria.
The activity of Parkin appears to be regulated at multiple lev-
els. The first is that Parkin appears to be auto-inhibited in its basal
state. Deletion or mutations in the Ubl domain, as well as addition
of Ubl-binding ligands or N-terminal tags, increase substantially
the autoubiquitination activity of Parkin (Chaugule et al., 2011).
Chaugule et al. proposed that Parkin auto-inhibition is maintained
by the interaction of the Ubl with the C-terminal domains of
Parkin, although exactly how this is achieved is unclear. ∆Ubl
Parkin does not bind E2 enzymes more strongly, but it exhibits
slightly faster E2∼Ub discharging kinetics (Chaugule et al., 2011).
Identifying the Ubl-binding site on Parkin’s C-terminal domains
will help resolve the mechanism of auto-inhibition.
The second level of Parkin regulation is through post-
translational modifications. There is strong evidence that phos-
phorylation plays a key role in the regulation of Parkin. First,
PINK1 kinase activity is required for the recruitment of Parkin to
depolarized mitochondria and for the activation of its ubiquitin
ligase activity (Geisler et al., 2010; Matsuda et al., 2010; Narendra
et al., 2010; Vives-Bauza et al., 2010; Lazarou et al., 2013). FLIM
studies suggest that Parkin and PINK1 are in close proximity on
depolarized mitochondria (Vives-Bauza et al., 2010). Immuno-
precipitations experiments have shown that Parkin and PINK1 are
part of the same complex (Xiong et al., 2009; Sha et al., 2010; Vives-
Bauza et al., 2010), but recent blue native PAGE (Lazarou et al.,
2012) and size-exclusion chromatography (Thomas et al., 2011)
studies showed that PINK1 and Parkin do not form a complex.
Thus, whether PINK1 and Parkin bind each other remains con-
troversial. However, in vitro experiments have demonstrated that
PINK1 phosphorylates Ser65 in the Ubl domain, which increases
its ubiquitin ligase activity (Kondapalli et al., 2012). Mutation of
Ser65 to Ala significantly impaired, but did not inhibit, translo-
cation of Parkin to depolarized mitochondria, suggesting that
Ser65 phosphorylation primes Parkin for recruitment (Shiba-
Fukushima et al., 2012). This effect could be mediated by the
disruption of the autoinhibitory interaction of the Ubl domain
(Chaugule et al., 2011). Phosphorylation can also negatively regu-
late Parkin: two groups found that Tyr143 phosphorylation by the
protein tyrosine kinase c-Abl reduces Parkin ubiquitination activ-
ity in vitro and in cells (Ko et al., 2010; Imam et al., 2011). Parkin
inactivation can also be brought upon oxidative stress (Winklhofer
et al., 2003) and covalent modifications of its essential cysteines,
either through S-nitrosylation or dopamine quinone adducts for-
mation (Chung et al., 2004; LaVoie et al., 2005). Finally, Parkin
levels may be regulated by autoubiquitination, and indeed its cou-
pling to the deubiquitinating enzyme ataxin-3 appears to regulate
its stability in cells (Durcan et al., 2011, 2012). Moreover, activation
of Parkin upon mitochondrial membrane depolarization induces
its degradation through the proteasome, suggesting that the auto-
inhibition of Parkin may protect itself from ubiquitin-mediated
degradation (Rakovic et al., 2012).
PINK1
The PINK1 (PARK6) gene was first described as PTEN-induced
putative kinase 1, a ubiquitous gene product whose expres-
sion was abolished in ovarian tumor tissues due to defect in
PTEN signaling (Unoki and Nakamura, 2001). Later, mutations
in PINK1 were found to cause autosomal recessive PD (Valente
et al., 2004). Mammalian PINK1 is a 581-residue protein, with
an N-terminal mitochondrial targeting sequence, a transmem-
brane helix, a serine/threonine kinase domain, and a C-terminal
domain of unknown function (Figure 2) (Beilina et al., 2005).
Studies in Drosophila showed that PINK1 has a role in the main-
tenance of mitochondria, and this role is intimately linked to
Parkin (Clark et al., 2006; Park et al., 2006). PINK1 was shown
to regulate HtrA2, a mitochondria protease which plays a role in
mitochondrial homeostasis (Plun-Favreau et al., 2007). PINK1
also regulates mitochondrial morphology in mammalian cells
(Poole et al., 2008), and is essential for the recruitment of Parkin to
mitochondria in cultured immortalized cells (Geisler et al., 2010;
Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al.,
2010; Lazarou et al., 2013) as well as in neurons (Wang et al., 2011;
Joselin et al., 2012). Physiologically, PINK1 deficiency leads to an
altered mitochondrial calcium buffering capacity and impaired
respiration caused by a reduced provision of electron transport
chain substrates (Gandhi et al., 2009). Recently, vitamin K2 was
found to rescue PINK1 deficiency through its capacity to carry
electrons (Vos et al., 2012). Thus PINK1 appears to have a clear
role in mitochondrial maintenance, which contributes to neuronal
survival.
Many of the mitochondrial functions carried by PINK1 depend
on its kinase activity, which has been the focus of a number of
studies. For example, whereas wild-type PINK1 can rescue Parkin
mitochondrial localization inPINK1−/−mouse embryonic fibrob-
lasts (MEFs), a kinase-dead mutant of PINK1 cannot (Geisler et al.,
2010; Matsuda et al., 2010; Narendra et al., 2010; Vives-Bauza et al.,
2010). Therefore a better understanding of PINK1 kinase activity
will give much insight into the function of PINK1. In vitro, recom-
binant PINK1 from different species can phosphorylate itself as
well as artificial substrates such as α-casein or the myelin basic
protein (Beilina et al., 2005; Silvestri et al., 2005; Woodroof et al.,
2011). However, the degree of activity appears to be dependent
on the PINK1 construction used, the expression system and the
species. In one instance, recombinant human PINK1 (112–496),
which was expressed in Escherichia coli and lacked the C-terminal
domain, was found to have increased activity compared to a con-
struct that contained the entire C-terminus (112–581) (Silvestri
et al., 2005). The human PINK1 kinase domain (112–496) was
also shown to be active in two earlier reports (Nakajima et al.,
2003; Beilina et al., 2005). However, later studies obtained opposite
results, although the construct boundaries were different: human
PINK1 (148–581) expressed in Sf9 insect cells was more active than
the isolated kinase domain (148–515) (Sim et al., 2006). In a sur-
vey of kinase activity across different PINK1 orthologs, Tribolium
castaneum (Tc) PINK1 was the most active and human PINK1 was
completely inactive (Woodroof et al., 2011). Moreover, TcPINK1
128–570 was more active than 155–570, and 155–486 had no activ-
ity. Overall, these studies suggest that the segments located at the
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FIGURE 2 | Structural model of PINK1. The domain boundaries of full-length
human PINK1 and PD mutations are displayed at the top. The domains are
colored as follows: mitochondrial targeting sequence (MTS, orange),
transmembrane helix (TM, red), N-terminal regulatory region (NT, white), N-
and C-terminal lobes (cyan and magenta), C-terminal domain (CTD, blue). The
three PINK1-specific insertions are colored in yellow. The coordinates for
human PINK1 156–511 (bottom cartoon) were obtained from the Protein
Model DataBase (PM0077187). The N- and C-terminal lobes are colored in
cyan and magenta, respectively. The ATP binding site is located in the cleft
between the two lobes. The three phosphorylation sites (Ser228, Ser402,
Thr281) and activation loop residues (Ser401, Ser402, and Arg407) are shown
as sticks. The model does not comprise the N-terminal (112–155) and
C-terminal (512–581) regions of the soluble domain, which cannot be
modeled by homology.
N- and C-termini of the kinase domain have regulatory functions,
and that the human PINK1 may be auto-inhibited. The impor-
tance of these regions in regulating PINK1 is supported by the
clustering of several PD mutations within these regions (Sim et al.,
2012).
Although there is no crystal structure of PINK1 available, the
similarity of its kinase domain to other serine/threonine kinases
led a number of groups to perform homology modeling (Beilina
et al., 2005; Mills et al., 2008; Cardona et al., 2011; Sim et al.,
2012). The protein is most similar to the calmodulin-dependent
kinase family, with which it shares a number of structural fea-
tures (Figure 2). Overall, the kinase domain consists of N- and
C-terminals lobes, which can be further subdivided into smaller
subdomains found in most kinases. The cleft between the two lobes
harbors the catalytic and ATP:Mg2+ binding sites (Cardona et al.,
2011). Three loop insertions in the N-terminal lobe are unique to
PINK1 and contain PD mutations, but the function of these inserts
is unknown. The PINK1 kinase domain also contains an activation
loop with two serine residues (Ser401-Ser402) whose phosphory-
lation was shown to be activating in other kinases (Nolen et al.,
2004). The activation loop also contains Arg407, a PD mutation
site and a potential site of interaction with a phosphorylated serine.
Similarly to Parkin, PINK1 is activated in cells upon mitochon-
drial membrane depolarization, but the mechanism of activation
remains unknown. Activation appears to be linked to its abun-
dance, localization and processing. Indeed, endogenous PINK1 is
found at low levels in cells as a result of its high turnover rate
(Lin and Kang, 2008; Narendra et al., 2010). PINK1 is normally
imported through the mitochondrial outer and inner membranes,
where it is successively cleaved by the mitochondrial processing
peptidase (MPP) and PARL/AFG3L2 (Jin et al., 2010; Deas et al.,
2011; Meissner et al., 2011; Greene et al., 2012). The MPP cleavage
site in PINK1 is unknown but is probably located in the residue
range amino acids 20–70, and PARL cleaves PINK1 between
Ala103-Phe104 in the transmembrane helix (Jin et al., 2010; Deas
et al., 2011; Kondapalli et al., 2012). This hydrophobic transmem-
brane helix was also suggested to act as a stop signal that prevents
further translocation into the matrix of the mitochondria (Zhou
et al., 2008; Lin and Kang, 2010; Becker et al., 2012). The resulting
52 kDa processing fragment may then undergo multiple fates: in
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its soluble form it is exported to the cytosol where it is degraded by
the proteasome (Lin and Kang, 2008; Narendra et al., 2010; Greene
et al., 2012). However, a recent study showed using an in vitro
import assay that the 52 kDa form can also be retained at the outer
mitochondrial membrane (OMM) via its C-terminal fragment
(Becker et al., 2012). Because mitochondrial import of PINK1 is
driven by the inner membrane proton gradient, membrane depo-
larization leads to the accumulation of unprocessed PINK1 at the
OMM (Narendra et al., 2010; Becker et al., 2012; Greene et al.,
2012). Prior studies had shown that the kinase domain of PINK1
faces the cytoplasm in its unprocessed mitochondria-tethered
form, which would enable PINK1 to phosphorylate both cytosolic
and OMM proteins (Zhou et al., 2008; Lin and Kang, 2010). The
complex membrane potential-dependence of PINK1 processing
and localization would thus serve to link PINK1’s activity to the
state of a mitochondrion, thereby suggesting a mechanism for the
detection of damaged mitochondria.
Recent studies point to the role of oligomerization and
autophosphorylation in the activation of PINK1. Indeed, upon
accumulation on the OMM, PINK1 forms a large 700 kDa multi-
meric complex with the translocase of the outer membrane (TOM)
complex (Becker et al., 2012; Lazarou et al., 2012). This was pro-
posed to allow for the rapid reimport and processing of PINK1
upon reestablishment of the membrane potential. Moreover,
PINK1 autophosphorylates when it accumulates on mitochon-
dria (Okatsu et al., 2012). In this study, Okatsu et al. showed that
Ser402 in the activation loop was required for autophosphoryla-
tion, although the authors could not detect direct phosphorylation
of this residue, but detected Ser228 phosphorylation. The double
mutant S228A/S402A failed to rescue GFP-Parkin mitochondrial
translocation in PINK1−/− MEFs, but S228D/S402D did rescue,
suggesting that PINK1 autophosphorylation is required for Parkin
activation. In a separate study, Kondapalli et al. (2012) found that
Thr257 in TcPINK1 (Thr282 in human) is phosphorylated upon
mitochondrial membrane depolarization, but mutation of that
residue did not affect Parkin activation. The ability of PINK1 to
multimerize and autophosphorylate is reminiscent of the acti-
vation mode of the homologous calmodulin-dependent kinases,
which form dodecameric ring structures where the monomers
phosphorylate each other upon binding Ca2+-bound calmodulin
(Rellos et al., 2010; Chao et al., 2011). Interestingly, Sha et al.
(2010) observed that PINK1, affinity-purified from mammalian
cells, could only phosphorylate Parkin in the presence of Ca2+.
Considering the role of PINK1 in regulating Ca2+ buffering by
mitochondria (Gandhi et al., 2009), future studies should address
how Ca2+ influences the activation of PINK1.
The identity of PINK1 substrate(s) remains a subject of much
debate. Studies using artificial peptide substrates indicated that
proline was the preferred amino acid at the+1 position (Woodroof
et al., 2011), and PREDIKIN predicts a weak consensus phos-
phorylation site (Sim et al., 2012). Early studies identified the
mitochondrial chaperone TRAP1 as a ligand and phosphoryla-
tion substrate of PINK1 (Pridgeon et al., 2007). More recently,
Miro, a protein involved in the axonal transport of mitochon-
dria, was also found to be phosphorylated by PINK1, resulting in
Parkin-mediated ubiquitination and degradation of Miro (Wang
et al., 2011). Although an earlier study failed to detect Parkin
phosphorylation by PINK1 in vitro (Vives-Bauza et al., 2010),
Parkin was later reported to be phosphorylated by PINK1 in vitro
and in vivo (Sha et al., 2010). More recently, in vitro assays with
recombinant proteins failed to detect significant phosphorylation
of either TRAP1 or Miro, but detected significant phosphory-
lation of Parkin on Ser65 in the Ubl (Kondapalli et al., 2012).
Parkin Ser65 phosphorylation was later confirmed and showed
to be required for efficient Parkin mitochondrial translocation
(Shiba-Fukushima et al., 2012). Therefore it appears that Parkin
could be the main substrate of PINK1, but the structural basis for
PINK1 kinase activity targeting the Parkin Ubl remains unknown.
DJ-1
The DJ-1 (PARK7 ) gene was first identified as an oncogene
(Nagakubo et al., 1997), and similarly to PINK1, was later asso-
ciated with familial PD (Bonifati et al., 2003). The protein has
neuroprotective activity and affects sensitivity to oxidative stress
(Canet-Aviles et al., 2004; Martinat et al., 2004). The effect could
be mediated through localization to mitochondria, where it can
reduce the oxidative stress induced by inhibitors of the respiratory
chain such as rotenone (Canet-Aviles et al., 2004; Blackinton et al.,
2009). DJ-1 deficiency leads to altered mitochondrial morphology
and increases the production of reactive oxygen species (ROS) as
a results of altered mitochondrial dynamics (Irrcher et al., 2010).
DJ-1-dependent mitochondrial defects can be rescued by addi-
tion of a cell-permeable glutathione precursor or Parkin/PINK1
overexpression (Thomas et al., 2011). Recently, DJ-1 was found
to negatively regulate PINK1-dependent Parkin translocation to
depolarized mitochondria in neurons, as a result of its ability to
control ROS generation (Joselin et al., 2012). Overall, functional
data indicate that DJ-1 protects cells from oxidative stress caused
by ROS, but how this is achieved at the molecular level is unclear.
The DJ-1 protein forms a single 20 kDa domain homologous
to a number of bacterial enzyme families such as ThiJ, a protein
involved in thiamine biosynthesis, and the Pfp1 protease (Bonifati
et al., 2003), as well as the YajL redox-sensitive chaperone (Gautier
et al., 2012). Its three-dimensional structure has been determined
by several groups nearly 10 years ago (Honbou et al., 2003; Lee
et al., 2003; Tao and Tong, 2003; Wilson et al., 2003), and shows a
compact globular domain with an active site Cys106 particularly
sensitive to oxidation (Figure 3). In solution, DJ-1 forms a sta-
ble dimer (Wilson et al., 2003). The PD mutation L166P, which
abolishes dimerization, also abrogates its neuroprotective activity,
suggesting that dimerization is essential to its function (Olzmann
et al., 2004).
In spite of this wealth of structural and homology data,
the precise biochemical function of DJ-1 has surprisingly not
yet been ascribed. Its closest homolog in bacteria, ThiJ, catal-
yses the phosphorylation of hydroxymethylpyrimidine (HMP)
to HMP-phosphate, a thiamine derivative (Mizote et al., 1996).
Under oxidative conditions the mammalian DJ-1 forms a cysteine-
sulfinic acid adduct in vitro and in cells, which has been proposed
to drive mitochondrial localization and neuroprotection (Canet-
Aviles et al., 2004; Blackinton et al., 2009). The molecular conse-
quences of adduct formation remain to be investigated, but it likely
modifies one of its many proposed enzymatic activities. DJ-1 bears
homology to bacterial proteases and although its Cys/His/Glu
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FIGURE 3 | Structure of DJ-1. The crystal structure of human DJ-1 (PDB
1P5F) was used to generate this dimer, which represents the biologically
active unit. The two subunits are colored in cyan and magenta. Residues of
the active site catalytic triad (Glu18, Cys106, His126) are shown as sticks.
The location of the PD mutation that disrupts dimerization (L166P) is
indicated by arrow.
catalytic triad is not optimally positioned for catalysis (Wilson
et al., 2003), DJ-1 was nonetheless shown to have proteolytic activ-
ity upon removal of its inhibitory C-terminal helix (Chen et al.,
2010). DJ-1 also prevents thermal aggregation of citrate synthase
in vitro as well as α-synuclein fibril formation in vitro and in vivo
(Shendelman et al., 2004), suggesting that DJ-1 could have chap-
erone activity similarly to the YajL bacterial chaperone (Gautier
et al., 2012). Interestingly, this chaperone activity is mediated only
by DJ-1 with an oxidized Cys106, thus providing a potential mole-
cular mechanism for the detection of ROS. An interesting new lead
for DJ-1 comes from the recent discovery of its glyoxalase activ-
ity (Lee et al., 2012). Glyoxals are small α-oxoaldehyde molecules
produced notably as a result of glucose oxidation in conditions of
rapid glycolysis. Glyoxals are toxic to the cell because they react
with proteins to form advanced glycation end-products (AGEs),
which have been implicated in a number of neurodegenerative
diseases including PD (Castellani et al., 1996). DJ-1 was shown to
protect MEFs and SH-SY5Y cells, as well as C. elegans, against gly-
oxals treatment. However, cells being already equipped with two
glutathione-dependent glyoxalases that remove reactive glyoxals,
it is unclear what additional roles could be played by DJ-1.
In addition to its proposed enzymatic activities, DJ-1 was also
found to bind many biological macromolecules, including RNA
(van der Brug et al., 2008), Cezanne (McNally et al., 2011), and
Bcl-XL (Ren et al., 2011). All of these interactions were shown
to depend on the oxidation state and/or the presence of Cys106.
However, considering the high reactivity of the active site cys-
teine, it is possible that these interactions are mediated through
non-specific covalent bond formation between the ligands and
Cys106 in DJ-1.
At present, it is difficult to assign a specific biochemical activity
to its function in vivo because all enzymatic activities described
for DJ-1 rely on the active site Cys106 reactivity. Indeed, Cys106
has a depressed pKa as a result of the proximity of Glu18, which
makes it a strong nucleophile (Witt et al., 2008). However, the
different activities proposed for DJ-1 are not necessarily exclu-
sive: both protease and glyoxalase activities would be diminished
upon oxidation of Cys106 or formation of a sulfinic acid deriv-
ative. An altered enzymatic activity even provides a molecular
mechanism for the proposed role of DJ-1 as a cellular redox sen-
sor. Finally, dopamine-derived quinones were recently shown to
covalently modify Cys106, which could potentially impair any of
its biological activities (Girotto et al., 2012). This is especially
relevant to PD, as oxidized dopamine side-products have been
suggested to play a role in the degeneration of dopaminergic neu-
rons (Hastings et al., 1996). Future work should therefore aim
to identify the biochemical function of DJ-1 most relevant to its
neuroprotective role.
CONCLUDING REMARKS
Over the past 15 years, deciphering the biochemical basis for the
function of Parkin, PINK1, and DJ-1 has led to great advances in
our understanding of the pathways and mechanisms involved in
PD. One challenge for the future will be to integrate the functions
of these three enzymes into a single coherent model of neuro-
protection. In recent years, a picture has emerged wherein the
hub of all three enzymes appears to be mitochondrial quality
control through regulation of fusion/fission and ROS genera-
tion. Indeed, deficiency in any of these three genes has been
shown to affect mitochondrial morphology and dynamics (Deng
et al., 2008; Poole et al., 2008; Irrcher et al., 2010), and these
defects can be rescued by overexpression of any of the other
three genes (Thomas et al., 2011). Mitochondrial fragmenta-
tion caused by a-synuclein overexpression can also be rescued
by overexpression of wild-type Parkin, PINK1, or DJ-1, but not
their functionally deficient mutants (Kamp et al., 2010). Overex-
pression of either PINK1 or Parkin lead to mitochondrial arrest
in the axons of cultured neurons, an effect which depends on
the kinase activitiy of PINK1 and the presence of Parkin in the
case of PINK1 overexpression (Wang et al., 2011). Finally, the
recruitment of Parkin to depolarized mitochondria in neurons
is influenced by oxidative stress levels and the presence of wild-
type, but not C106A, DJ-1 (Joselin et al., 2012). These cross-talks
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between Parkin, PINK1, and DJ-1 activities are most likely medi-
ated through OMM proteins involved in fusion/fission such as
Mfn1/2 or Fis1 (Yang et al., 2008; Cui et al., 2010; Rakovic et al.,
2011; Zhang et al., 2012), or regulators of motility such as Miro1/2
(Wang et al., 2011). Future studies should examine in more details
the functional relationships between these three proteins at the
biochemical level.
Another important goal is to gain more detailed structural
insight for Parkin and PINK1, which will lead to a better under-
standing of their biochemical functions and regulatory mecha-
nisms. Taken together, the structure and function of this trio
of enzymes will lead to the design of new therapies that will
enhance and/or correct the function of these proteins, when they
are defective in PD.
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